– USA, TX – Elevage Medical Technologies, a portfolio company of Patient Square Capital, today announced the addition of Dr. Josh Makower to its Board of Directors.
About Dr. Josh Makower
Dr. Josh Makower is the Yock Family Professor of Medicine and Bioengineering at the Stanford University Schools of Medicine and Engineering and the Co-Founder and Director of the Stanford Byers Center for Biodesign. Dr. Makower is also the Founder & Executive Chairman of ExploraMed, a medical device incubator that has created eleven companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard, and TransVascular, acquired by Medtronic.
Dr. Josh Makower serves on the boards of Revelle Aesthetics, ExploraMed, Moximed, X9, Willow, and Coravin. He holds over 300 patents and patent applications. He received an MBA from Columbia University, an M.D. from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT. Additionally, Dr. Makower is a Member of the National Academy of Engineering, a Fellow of The National Academy of Inventors and The American Institute for Medical and Biological Engineering, and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
About Elevage Medical Technologies
Elevage Medical Technologies is a platform created by Patient Square Capital dedicated to supporting medical device and technology companies that can meaningfully improve health outcomes and quality of life for patients. Through capital investment and strategic operational support, Elevage strives to accelerate the pace of innovation in the medical device and technology space.
For more information: https://elevagemedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
